AT419840T - Oral aqueous suspension, microcapsules containing, for controlled release of active - Google Patents

Oral aqueous suspension, microcapsules containing, for controlled release of active

Info

Publication number
AT419840T
AT419840T AT03745832T AT03745832T AT419840T AT 419840 T AT419840 T AT 419840T AT 03745832 T AT03745832 T AT 03745832T AT 03745832 T AT03745832 T AT 03745832T AT 419840 T AT419840 T AT 419840T
Authority
AT
Austria
Prior art keywords
active
controlled release
aqueous suspension
microcapsules containing
oral aqueous
Prior art date
Application number
AT03745832T
Other languages
German (de)
Inventor
Catherine Castan
Florence Guimberteau
Remi Meyrueix
Original Assignee
Flamel Tech Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0204409 priority Critical
Priority to FR0210847A priority patent/FR2843881B1/en
Application filed by Flamel Tech Sa filed Critical Flamel Tech Sa
Publication of AT419840T publication Critical patent/AT419840T/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-arylpropionic acids, ethacrynic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5015Organic compounds, e.g. fats, sugars
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5026Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
AT03745832T 2002-04-09 2003-04-07 Oral aqueous suspension, microcapsules containing, for controlled release of active AT419840T (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FR0204409 2002-04-09
FR0210847A FR2843881B1 (en) 2002-09-02 2002-09-02 oral pharmaceutical formulation in the form of aqueous suspension of microcapsules for modified release principle (s) active (s)

Publications (1)

Publication Number Publication Date
AT419840T true AT419840T (en) 2009-01-15

Family

ID=28793279

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03745832T AT419840T (en) 2002-04-09 2003-04-07 Oral aqueous suspension, microcapsules containing, for controlled release of active

Country Status (16)

Country Link
US (5) US7906145B2 (en)
EP (1) EP1492511B3 (en)
JP (1) JP4732696B2 (en)
KR (1) KR101061351B1 (en)
CN (1) CN100553625C (en)
AT (1) AT419840T (en)
AU (1) AU2003246792B2 (en)
BR (1) BRPI0309142B8 (en)
CA (1) CA2480826C (en)
DE (1) DE60325709D1 (en)
ES (1) ES2320438T7 (en)
HK (1) HK1079448A1 (en)
IL (2) IL164222D0 (en)
MX (1) MXPA04009968A (en)
PT (1) PT1492511E (en)
WO (1) WO2003084518A2 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
FR2830447B1 (en) * 2001-10-09 2004-04-16 Flamel Tech Sa oral dosage form microparticle for the delayed and controlled release of active pharmaceutical ingredients
CA2480826C (en) 2002-04-09 2012-02-07 Flamel Technologies Oral pharmaceutical formulation in the form of microcapsule aqueous suspension allowing modified release of active ingredient(s)
FR2842736B1 (en) 2002-07-26 2005-07-22 Flamel Tech Sa oral pharmaceutical formulation in the form of a plurality of microcapsules for the sustained release principle (s) active (s) slightly soluble (s)
FR2842735B1 (en) * 2002-07-26 2006-01-06 Flamel Tech Sa Microcapsules modified release of poorly soluble active ingredients for the oral administration
FR2881652B1 (en) * 2005-02-08 2007-05-25 Flamel Technologies Sa microparticulate oral pharmaceutical form anti-mesuage
JP2008530185A (en) * 2005-02-21 2008-08-07 フラメル・テクノロジーFlamel Technologies Losartan oral pharmaceutical form
FR2882259A1 (en) * 2005-02-21 2006-08-25 Flamel Technologies Sa Use of a controlled release losartan oral dosage form, to decrease the inter individual gap of standard deviation of maximum concentration of the losartan, independent of administration of losartan before or after the meals
FR2882260A1 (en) * 2005-02-21 2006-08-25 Flamel Technologies Sa oral pharmaceutical form multimicroparticulate the modified release of receptor antagonists of angiotensin II
FR2884145A1 (en) * 2005-04-06 2006-10-13 Flamel Technologies Sa Use of a controlled release losartan oral dosage form, to decrease the inter individual gap of standard deviation of maximum concentration of the losartan, independent of administration of losartan before or after the meals
GB0507167D0 (en) * 2005-04-08 2005-05-18 Glaxosmithkline Consumer Healt Composition
MX2007014068A (en) * 2005-05-10 2008-02-07 Novartis Ag Modified release famciclovir pharmaceutical compositions.
FR2889810A1 (en) * 2005-05-24 2007-02-23 Flamel Technologies Sa Oral medicinal form, microparticular, anti-measurement
WO2007022105A2 (en) * 2005-08-12 2007-02-22 Rubicon Research Pvt. Ltd. Stable pharmaceutical compositions, processes for making the same, and methods of their use
KR101495146B1 (en) 2006-03-16 2015-02-24 트리스 파마 인코포레이티드 Modified release formulations containing drug - ion exchange resin complexes
US20090111736A1 (en) * 2007-10-29 2009-04-30 Sri International Orally-Absorbed Solid Dose Formulation for Vancomycin
EP2228054A1 (en) 2009-03-13 2010-09-15 ITALFARMACO S.p.A. Riluzole aqueous suspensions
WO2011077451A2 (en) * 2009-12-22 2011-06-30 Abbott Healthcare Private Limited Controlled release pharmaceutical composition
US8287903B2 (en) 2011-02-15 2012-10-16 Tris Pharma Inc Orally effective methylphenidate extended release powder and aqueous suspension product
US20140178479A1 (en) 2011-08-12 2014-06-26 Perosphere, Inc. Concentrated Felbamate Formulations for Parenteral Administration
US9254281B2 (en) * 2011-09-12 2016-02-09 Wright State University Composition and method for the treatment of neurodegeneration
CN102579398A (en) * 2011-12-31 2012-07-18 沈阳药科大学 Enteric microcapsule with function of balancing bad taste of medicament and preparation method of enteric microcapsule
CN102552163B (en) * 2012-01-05 2013-12-04 金陵药业股份有限公司 Metoprolol tartrate sustained release pellet and preparation method thereof
AU2013302657B2 (en) 2012-08-15 2018-08-09 Tris Pharma, Inc. Methylphenidate extended release chewable tablet
RU2016147008A (en) * 2014-05-01 2018-06-04 Сан Фармасьютикал Индастриз Лимитед Liquid compositions with sustained release of metformin
US9962336B2 (en) 2014-05-01 2018-05-08 Sun Pharmaceutical Industries Limited Extended release suspension compositions
US10258583B2 (en) 2014-05-01 2019-04-16 Sun Pharmaceutical Industries Limited Extended release liquid compositions of guanfacine
WO2015166473A1 (en) 2014-05-01 2015-11-05 Sun Pharmaceutical Industries Limited Extended release suspension compositions
JP6335692B2 (en) * 2014-07-08 2018-05-30 ライオン株式会社 Liquid oral formulation
BR112017001968A2 (en) 2014-07-30 2017-11-21 Sun Pharmaceutical Industries Ltd Packaging two chambers for an oral liquid pharmaceutical composition multidose
RU2017123366A3 (en) * 2014-12-05 2019-01-10
CA3003028A1 (en) * 2015-10-30 2017-05-04 Cmp Development Llc Spironolactone aqueous compositions
US10238803B2 (en) 2016-05-02 2019-03-26 Sun Pharmaceutical Industries Limited Drug delivery device for pharmaceutical compositions

Family Cites Families (289)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029884A (en) 1971-03-18 1977-06-14 Abbott Laboratories Adenosine-5'-carboxylic acid amides
US3864483A (en) 1972-03-22 1975-02-04 Abbott Lab Adenosine-5{40 -carboxylic acid amides
CA1019727A (en) 1971-03-18 1977-10-25 Abbott Laboratories Adenosine-5'-carboxylic acid amides
US3980766A (en) 1973-08-13 1976-09-14 West Laboratories, Inc. Orally administered drug composition for therapy in the treatment of narcotic drug addiction
US3927216A (en) 1971-06-01 1975-12-16 Icn Pharmaceuticals 1,2,4-Triazol E-3-carboxamides for inhibiting virus infections
US3914415A (en) 1973-06-14 1975-10-21 Abbott Lab Adenosine-5{40 -carboxylic acid amides
US3914414A (en) 1973-06-14 1975-10-21 Abbott Lab Method of increasing coronary pO{HD 2 {B in mammals
US4351337A (en) 1973-05-17 1982-09-28 Arthur D. Little, Inc. Biodegradable, implantable drug delivery device, and process for preparing and using the same
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
US3966917A (en) 1974-07-30 1976-06-29 Abbott Laboratories Platelet aggregation inhibitors
US3892769A (en) 1973-07-20 1975-07-01 Merck & Co Inc Acetaminophen esters of aryl salicylic acids
DE2417465A1 (en) 1974-04-10 1975-10-30 Lester R Wellman Sealed container opening and reclosing system - has locking section joined by fold line to reinforcing anchoring section
DE2530563C2 (en) 1975-07-09 1986-07-24 Bayer Ag, 5090 Leverkusen, De
FR2313915B1 (en) 1976-01-26 1980-06-13 Corneille Gilbert
NO154918C (en) 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate for preparing therapeutically active derivatives of 3,4,5-trihydroksypiperidin.
SE7804231A (en) 1978-04-14 1979-10-15 Haessle Ab Gastric acid secretion Mediterranean
US4308251A (en) 1980-01-11 1981-12-29 Boots Pharmaceuticals, Inc. Controlled release formulations of orally-active medicaments
JPS6056122B2 (en) 1980-05-21 1985-12-09 Shionogi & Co
US4321253A (en) 1980-08-22 1982-03-23 Beatty Morgan L Suspension of microencapsulated bacampicillin acid addition salt for oral, especially pediatric, administration
US4454309A (en) 1980-11-12 1984-06-12 Tyndale Plains-Hunter, Ltd. Polyurethane polyene compositions
JPS6351735B2 (en) 1981-05-29 1988-10-14 Tanabe Seiyaku Co
US4443549A (en) 1981-10-19 1984-04-17 Molecular Genetics, Inc. Production of monoclonal antibodies against bacterial adhesins
US4434153A (en) 1982-03-22 1984-02-28 Alza Corporation Drug delivery system comprising a reservoir containing a plurality of tiny pills
US4507276A (en) 1982-08-20 1985-03-26 Bristol-Myers Company Analgesic capsule
US4461759A (en) 1983-01-03 1984-07-24 Verex Laboratories, Inc. Constant release rate solid oral dosage formulations of veropamil
HU187215B (en) 1983-01-26 1985-11-28 Egyt Gyogyszervegyeszeti Gyar Method for producing pharmaceutical product of high actor content and prolonged effect
US4833905A (en) 1983-06-03 1989-05-30 Micromatic Textron Inc. Method for splining clutch hubs with close tolerance spline bellmouth and oil seal surface roundness
JPH0231079B2 (en) 1983-08-30 1990-07-11 Sankyo Co Chiazorijinjudotaioyobisonoseizoho
JPH0157087B2 (en) 1983-11-04 1989-12-04 Takeda Chemical Industries Ltd
US4894240A (en) 1983-12-22 1990-01-16 Elan Corporation Plc Controlled absorption diltiazem formulation for once-daily administration
IL75400A (en) 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPH0244473B2 (en) 1984-08-16 1990-10-04 Takeda Chemical Industries Ltd Pirijinjudotaioyobisonoseizoho
AU4640985A (en) 1984-08-31 1986-03-06 Nippon Chemiphar Co. Ltd. Benzimidazole derivatives
DE3581471D1 (en) 1984-10-19 1991-02-28 Battelle Memorial Institute By microorganisms biodegradable polypeptide and its use for the progressive royalty of drugs.
EP0198769A3 (en) 1985-04-12 1987-09-02 Forest Laboratories, Inc. Floating sustained release therapeutic compositions
EP0202027A1 (en) 1985-04-18 1986-11-20 Sumitomo Chemical Company, Limited A herbicidal composition
US4728512A (en) 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
LU85943A1 (en) 1985-06-12 1987-01-13 Galephar Tablets Pharmaceutical allowing aisee administration of pellets, their preparation and their use
IT1185177B (en) * 1985-07-03 1987-11-04 Metalvuoto Films Spa Device for making metallized plastic films having well-demarcated areas without metalization
US5002551A (en) 1985-08-22 1991-03-26 Johnson & Johnson Medical, Inc. Method and material for prevention of surgical adhesions
US4693896A (en) 1985-10-07 1987-09-15 Fmc Corporation Ethylcellulose-coated, gastric-disintegrable aspirin tablet
DE3543999A1 (en) 1985-12-13 1987-06-19 Bayer Ag Highly pure acarbose
CA1327010C (en) 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
AU591248B2 (en) 1986-03-27 1989-11-30 Kinaform Technology, Inc. Sustained-release pharaceutical preparation
SE8601624D0 (en) 1986-04-11 1986-04-11 Haessle Ab New Pharmaceutical Preparations
WO1987007833A1 (en) 1986-06-20 1987-12-30 Shacknai Jonah Oral sustained release medicament
KR950009089B1 (en) 1986-08-18 1995-08-14 샘 제이. 밀스타인 Delivery systems for pharmaceutical agents
IT1200217B (en) 1986-09-30 1989-01-05 Valducci Roberto Membrane for pharmaceutical and industrial use
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
SE8605515D0 (en) 1986-12-22 1986-12-22 Astra Laekemedel Ab A liquid dosage form for oral administration of a Pharmaceutically Active Substance
US5026560A (en) 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
DE3887179T2 (en) 1987-03-02 1994-06-16 Brocades Pharma Bv A pharmaceutical composition, pharmaceutical granule and processes for their preparation.
GB8705083D0 (en) 1987-03-04 1987-04-08 Euro Celtique Sa Spheroids
US4902513A (en) * 1987-07-31 1990-02-20 Jean Carvais Oral sustained release medicament
US4837031A (en) 1987-09-17 1989-06-06 Mallinckrodt, Inc. Compositions containing ibuprofen
US4961932A (en) 1987-10-26 1990-10-09 Alza Corporation Plurality of tiny pills in liquid dosage form
DE3810757C2 (en) 1988-03-30 1990-09-20 Fa. Carl Freudenberg, 6940 Weinheim, De
US5268182A (en) 1988-06-24 1993-12-07 Abbott Laboratories Sustained-release drug dosage units of terazosin
FR2634377B1 (en) 1988-06-30 1991-09-27 Cortial New pharmaceutical form is sustained release-based resin of a complex active-principle
US5028434A (en) 1988-07-21 1991-07-02 Alza Corporation Method for administering nilvadipine for treating cardiovascular symptoms
IT1226940B (en) * 1988-09-16 1991-02-22 Recordati Chem Pharm controlled release therapeutic system for liquid pharmaceutical formulations
FI894611A (en) 1988-09-30 1990-03-31 May & Baker Ltd Granulaera farmaceutisk preparat.
US5186930A (en) * 1988-11-14 1993-02-16 Schering Corporation Sustained release oral suspensions
US4999189A (en) * 1988-11-14 1991-03-12 Schering Corporation Sustained release oral suspensions
IT1227899B (en) 1988-12-23 1991-05-14 Poli Ind Chimica Spa total or partial coating of pharmaceutical active ingredients and relative compositions
CA2007181C (en) 1989-01-06 1998-11-24 Angelo Mario Morella Sustained release pharmaceutical composition
FR2642080B1 (en) 1989-01-23 1992-10-02 Onera (Off Nat Aerospatiale) Polysilanes and their method of preparing
US4948581A (en) 1989-02-17 1990-08-14 Dojin Iyaku-Kako Co., Ltd. Long acting diclofenac sodium preparation
US5026559A (en) 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5084278A (en) 1989-06-02 1992-01-28 Nortec Development Associates, Inc. Taste-masked pharmaceutical compositions
AU632602B2 (en) 1989-08-02 1993-01-07 John David Arnold Method and preparation for reducing risk of myocardial infarction
NZ233975A (en) 1989-08-16 1992-06-25 Sterling Drug Inc Aspirin granules coated with a gastroprotectant
EP0550436A1 (en) 1989-11-06 1993-07-14 Alkermes Controlled Therapeutics, Inc. Protein microspheres and methods of using them
WO1991006286A1 (en) 1989-11-06 1991-05-16 Enzytech, Inc. Method for producing protein microspheres
US5248516A (en) 1989-12-19 1993-09-28 Fmc Corporation Film-forming composition: method of producing same and use for coating pharmaceuticals and foods and the like
GB9002495D0 (en) 1990-02-05 1990-04-04 Monsanto Europe Sa Glyphosate compositions
US5206030A (en) 1990-02-26 1993-04-27 Fmc Corporation Film-forming composition and use for coating pharmaceuticals, foods and the like
IT1246383B (en) 1990-04-17 1994-11-18 Eurand Int A method for masking the taste of drugs
CA2085342A1 (en) 1990-06-14 1991-12-15 Milton R. Kaplan Stable aqueous drug suspensions
SE9002206D0 (en) 1990-06-20 1990-06-20 Haessle Ab New compounds
PL165898B1 (en) 1990-06-20 1995-02-28 Astra Ab Method of obtaining novel derivatives of dialkoxy pyridinyl benzimidazole
WO1992001446A1 (en) 1990-07-20 1992-02-06 Aps Research Limited Sustained-release formulations
SE9002684D0 (en) 1990-08-17 1990-08-17 Malvac Foundation C O Peter Pe New peptides and Their Use
EP0477135A1 (en) 1990-09-07 1992-03-25 Warner-Lambert Company Chewable spheroidal coated microcapsules and methods for preparing same
GB9022788D0 (en) 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
US5219895A (en) 1991-01-29 1993-06-15 Autogenesis Technologies, Inc. Collagen-based adhesives and sealants and methods of preparation and use thereof
US5431922A (en) 1991-03-05 1995-07-11 Bristol-Myers Squibb Company Method for administration of buspirone
GB9104854D0 (en) 1991-03-07 1991-04-17 Reckitt & Colmann Prod Ltd Sustained release compositions
FI922107A0 (en) 1991-05-10 1992-05-08 Faulding F H & Co Ltd Mikrokapselkomposition Science foerfarande.
US5286497A (en) 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
IT1250421B (en) 1991-05-30 1995-04-07 Recordati Chem Pharm Pharmaceutical composition with controlled release properties' bio-adhesive.
US5571533A (en) 1992-02-07 1996-11-05 Recordati, S.A., Chemical And Pharmaceutical Company Controlled-release mucoadhesive pharmaceutical composition for the oral administration of furosemide
FR2679451B1 (en) 1991-07-22 1994-09-09 Prographarm Laboratoires Compresses multiparticulate fast disintegrating.
US5464632C1 (en) 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
KR100259989B1 (en) 1991-10-01 2000-08-01 모리다 가쓰라 Prolonged release microparticle preparation and production of the same
US5656295A (en) 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5409709A (en) 1991-11-29 1995-04-25 Lion Corporation Antipyretic analgesic preparation containing ibuprofen
DE4200821A1 (en) * 1992-01-15 1993-07-22 Bayer Ag A taste masked pharmaceutical agent
US5272137A (en) * 1992-02-14 1993-12-21 Mcneil-Pfc, Inc. Aqueous pharmaceutical suspension for pharmaceutical actives
US5286495A (en) 1992-05-11 1994-02-15 University Of Florida Process for microencapsulating cells
KR940003548U (en) 1992-08-14 1994-02-21 김형술 Laundry dryers
IL103224A (en) 1992-09-18 1998-08-16 Teva Pharma Stabilized pharmaceutical compositions containing derivatives of vitamins d2 and d3
AU5592694A (en) 1992-11-05 1994-05-24 Merck & Co., Inc. Drug delivery device
IT1256651B (en) 1992-12-11 1995-12-12 Giancarlo Santus controlled-release pharmaceutical composition in liquid suspension
US5594016A (en) 1992-12-28 1997-01-14 Mitsubishi Chemical Corporation Naphthalene derivatives
FR2704146B1 (en) 1993-04-19 1995-07-13 Cripdom Microcapsules of controlled release acetylsalicylic acid.
SE9301830D0 (en) 1993-05-28 1993-05-28 Ab Astra New compounds
FR2708932B1 (en) 1993-08-10 1995-11-10 Flamel Tech Sa Process for the preparation of polyamino acids.
EP1442745A1 (en) 1993-10-07 2004-08-04 Euro-Celtique Orally administrable opioid formulations having extended duration of effect
US5858398A (en) 1994-11-03 1999-01-12 Isomed Inc. Microparticular pharmaceutical compositions
GB9401894D0 (en) 1994-02-01 1994-03-30 Rhone Poulenc Rorer Ltd New compositions of matter
IT1269578B (en) * 1994-04-22 1997-04-08 Chiesi Farma Spa Inclusion complexes multicomponent high solubility 'consisting of an acid type drug, a cyclodextrin and a base.
CA2189658C (en) 1994-05-06 2000-10-31 William J. Curatolo Controlled-release dosage forms of azithromycin
IT1270594B (en) 1994-07-07 1997-05-07 Recordati Chem Pharm A pharmaceutical composition for controlled release of moguisteine ​​in liquid suspension
JPH0873345A (en) 1994-09-05 1996-03-19 Terumo Corp Pharmaceutical preparations
DE4432757A1 (en) 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmaceutical composition comprising metformin and methods of their production
FR2724563B1 (en) 1994-09-15 1997-02-14
FR2725623B1 (en) 1994-10-18 1997-02-21
GB9423588D0 (en) 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
KR0167613B1 (en) 1994-12-28 1999-01-15 한스 루돌프 하우스, 니콜 케르커 Cyclosporin-containing soft capsule compositions
US5834024A (en) 1995-01-05 1998-11-10 Fh Faulding & Co. Limited Controlled absorption diltiazem pharmaceutical formulation
JP2690276B2 (en) 1995-01-10 1997-12-10 科学技術振興事業団 Electrostatically bonded polymeric micelle drug carrier and the drug
FR2732218B1 (en) 1995-03-28 1997-08-01 Flamel Tech Sa Particles basic polyamino acid (s) and may be used as the principle vectors (s) active (s) and their processes of preparation
US5750468A (en) 1995-04-10 1998-05-12 Monsanto Company Glyphosate formulations containing etheramine surfactants
US5674529A (en) 1995-06-06 1997-10-07 Church & Dwight Co., Inc. Alkalinizing potassium salt controlled release preparations
US5945124A (en) 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
GB9514285D0 (en) 1995-07-13 1995-09-13 Univ Nottingham Polymeric lamellar substrate particles for drug delivery
DE69617036T2 (en) 1995-09-07 2002-07-11 Smithkline Beecham Corp Use of a amoxicillin and clavulanate containing pediatric pharmaceutical formulation
AT334689T (en) 1995-11-13 2006-08-15 Univ Northwest Administration medium for analgesic, antiinflammatory and antipyretic agents and pharmaceutical compositions containing such a medium and ingredients
IT1276130B1 (en) 1995-11-14 1997-10-27 Gentili Ist Spa Association glibenclamide-metformin, pharmaceutical compositions containing it and their use in the treatment of diabetes mellitus type
CA2238975A1 (en) 1995-12-12 1997-06-19 Jeffrey G. Werrmann New use for losartan
SE9600071D0 (en) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active Ingredients
US6245351B1 (en) 1996-03-07 2001-06-12 Takeda Chemical Industries, Ltd. Controlled-release composition
FR2746035B1 (en) 1996-03-15 1998-06-12 Microparticles of composite gel may be used as vector (s) ingredient (s) active (s), one of their methods of preparation and their applications
US20030064108A1 (en) 1996-04-23 2003-04-03 Stefan Lukas Taste masked pharmaceutical compositions
DE19628341C2 (en) * 1996-07-13 1998-09-17 Sihl Gmbh Aqueous ink jet recording material and use for making waterfast and lightfast recordings on this material
FR2752732B1 (en) * 1996-08-28 1998-11-20 Pf Medicament DOSAGE FORM a sustained release of milnacipran
US5780055A (en) 1996-09-06 1998-07-14 University Of Maryland, Baltimore Cushioning beads and tablet comprising the same capable of forming a suspension
WO1998024411A2 (en) 1996-12-04 1998-06-11 Bristol-Myers Squibb Company Method for oral administration of buspirone
WO1998026803A1 (en) 1996-12-19 1998-06-25 Daiichi Pharmaceutical Co., Ltd. Pharmaceutical composition for oral administration
FR2759083B1 (en) 1997-02-06 1999-04-30 Dev Des Utilisations Du Collag Collagenic material particularly useful for the prevention of Postoperative adhesions
US5981761A (en) 1997-03-27 1999-11-09 Solutia Inc. Crosslinked polyaspartate salts a process for their production
US6162463A (en) 1997-05-01 2000-12-19 Dov Pharmaceutical Inc Extended release formulation of diltiazem hydrochloride
BR9809193A (en) 1997-05-30 2000-08-01 Monsanto Co Method and compositions for promoting biological effectiveness of exogenous chemicals in plants
AT302597T (en) 1997-06-06 2005-09-15 Depomed Inc In the stomach, lingering oral dosage forms of water-soluble drugs with controlled release
JP3677156B2 (en) 1997-09-05 2005-07-27 武田薬品工業株式会社 Medicine
CA2302275C (en) 1997-09-19 2009-12-08 Shire Laboratories Inc. Solid solution beadlet
US6472373B1 (en) 1997-09-21 2002-10-29 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
FR2771291B1 (en) 1997-11-21 2000-02-25 Ethypharm Lab Prod Ethiques Spheroids, process for the preparation and pharmaceutical compositions
US6444246B1 (en) 1997-12-16 2002-09-03 Mccormick & Company, Inc. Cake-resistant, hygroscopically sensitive materials and process for producing the same
SE9704869D0 (en) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
CA2314896C (en) 1997-12-22 2005-09-13 Euro-Celtique, S.A. A method of preventing abuse of opioid dosage forms
BR9908911A (en) 1998-03-19 2001-10-02 Squibb Bristol Myers Co biphasic system and distribution process by controlled release of high solubility pharmaceutical substances
EP1062955A1 (en) 1998-03-20 2000-12-27 Kowa Co., Ltd. Medicinal compositions adhering to stomach/duodenum
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US6184220B1 (en) * 1998-03-27 2001-02-06 Boehringer Ingelheim Pharma Kg Oral suspension of pharmaceutical substance
AT318132T (en) 1998-03-30 2006-03-15 Jagotec Ag Compositions comprising microparticles of water insoluble substances, as well as processes for their preparation
US5945123A (en) 1998-04-02 1999-08-31 K-V Pharmaceutical Company Maximizing effectiveness of substances used to improve health and well being
PT974356E (en) 1998-07-15 2004-02-27 Merck Sante Sas Tablets comprehensing a metformin and glibenclamide combination
AU4800999A (en) 1998-07-28 2000-02-21 Tanabe Seiyaku Co., Ltd. Preparation capable of releasing drug at target site in intestine
US20020068365A1 (en) 1998-07-28 2002-06-06 Eric H. Kuhrts Controlled release nitric oxide producing agents
US6179862B1 (en) 1998-08-14 2001-01-30 Incept Llc Methods and apparatus for in situ formation of hydrogels
US6099862A (en) 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
US6303607B1 (en) 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
JP2002525311A (en) 1998-10-01 2002-08-13 エラン ファーマ インターナショナル,リミティド Controlled release nanoparticle composition
JP2000128774A (en) 1998-10-26 2000-05-09 Tanabe Seiyaku Co Ltd Production of globular, fine grain including medicine
AT411011T (en) 1998-11-02 2008-10-15 Elan Pharma Int Ltd Multiparticulate composition of methylphenidate with modified release
YU37301A (en) 1998-11-12 2005-06-10 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
FR2786098B1 (en) 1998-11-20 2003-05-30 Flamel Tech Sa Particles based on polyamino acid (s) and may be used as vectors principle (s) active (s), colloidal suspension comprising them and their processes of manufacture
US6419960B1 (en) 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
DE19860698A1 (en) 1998-12-30 2000-07-06 Hexal Ag New pharmaceutical composition
US7785625B2 (en) 2000-01-14 2010-08-31 Lg Life Sciences, Limited Lipophilic-coated microparticle containing a protein drug and formulation comprising same
JP3645816B2 (en) 1999-02-23 2005-05-11 ユハン・コーポレーション Pharmaceutical Capsule compositions containing loratadine and pseudoephedrine
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6566560B2 (en) 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
CO5170471A1 (en) 1999-04-13 2002-06-27 Beecham Pharmaceutical Pte Ltd Modified release tablets including amoxycillin and potassium clavulanate
US7576131B2 (en) 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
SE9902386D0 (en) 1999-06-22 1999-06-22 Astra Ab New formulation
EP1204406A2 (en) 1999-07-29 2002-05-15 Roxane Laboratories, Inc. Opioid sustained-released formulation
US20030118641A1 (en) 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
BR0013825A (en) * 1999-08-31 2002-07-23 Gruenenthal Chemie tramadol presentation forms
DE19940740A1 (en) * 1999-08-31 2001-03-01 Gruenenthal Gmbh pharmaceutical salts
ES2168043B1 (en) 1999-09-13 2003-04-01 Esteve Labor Dr solid oral dosage form modified release containing a benzimidazole compound labile in acid medium.
US6264983B1 (en) 1999-09-16 2001-07-24 Rhodia, Inc. Directly compressible, ultra fine acetaminophen compositions and process for producing same
CO5200844A1 (en) 1999-09-17 2002-09-27 Novartis Ag A combination comprising nateglinide as less other antidiabetic compound used for the treatment of metabolic disorders, especially diabetes or a disease or condition associated with dibetes
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
RU2275915C2 (en) 1999-11-03 2006-05-10 Бристол-Маерс Сквибб Компани Method for diabetes treatment
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
FR2801226B1 (en) 1999-11-23 2002-01-25 Flamel Tech Sa colloidal suspension of submicron particles of active ingredients vectorization and method of preparation
DE19961897A1 (en) * 1999-12-20 2001-06-28 Basf Ag Use of a film coating as taste Coating of pharmaceutical dosage forms
US6248359B1 (en) 2000-01-05 2001-06-19 Laboratorios Phoenix U.S.A., Inc. Multi-tablet oxybutynin system for treating incontinence
SI2092936T1 (en) 2000-02-08 2013-07-31 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
WO2001058424A1 (en) 2000-02-09 2001-08-16 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Floating drug delivery composition
US6627223B2 (en) * 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US6815542B2 (en) 2000-06-16 2004-11-09 Ribapharm, Inc. Nucleoside compounds and uses thereof
US6534651B2 (en) 2000-04-06 2003-03-18 Inotek Pharmaceuticals Corp. 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof
US6951534B2 (en) 2000-06-13 2005-10-04 Acorn Cardiovascular, Inc. Cardiac support device
JP2002003366A (en) 2000-06-23 2002-01-09 Freunt Ind Co Ltd Aqueous coating composition for solid medicine
CN1296387C (en) 2000-07-05 2007-01-24 旭化成株式会社 Cellulose powder
FR2811571B1 (en) 2000-07-11 2002-10-11 Flamel Tech Sa An oral pharmaceutical composition, for the controlled release and prolonged absorption of an active ingredient
IT1318625B1 (en) 2000-07-14 2003-08-27 Roberto Valducci solid oral pharmaceutical formulations multifasicoph-dependent release.
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US7074417B2 (en) 2000-10-13 2006-07-11 Advancis Pharmaceutical Corporation Multiple-delayed release anti-viral product, use and formulation thereof
US6499158B1 (en) 2000-10-30 2002-12-31 Steris, Inc. Surgical table top and accessory clamp used thereon
FR2816840B1 (en) 2000-11-17 2004-04-09 Flamel Tech Sa Medicament-based microcapsules of anti-hyperclycemiant has sustained release and method of preparing
DE60138044D1 (en) 2000-12-28 2009-04-30 Tap Pharmaceutical Prod Inc Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate and bicarbonatsalzkombination
EP1363604A2 (en) 2001-02-14 2003-11-26 Glaxo Wellcome S.A. Pharmaceutical formulation
BR0207932A (en) * 2001-03-05 2004-03-02 Ortho Mcneil Pharm Inc Pharmaceutical Compositions Taste Masked
FR2821745B1 (en) 2001-03-09 2004-07-02 Ethypharm Lab Prod Ethiques Granules and coated granules to mask taste
BR0102252B1 (en) 2001-04-10 2013-10-22 System for controlled release of the antagonist of angiotensin II AT1 receptor, pharmaceutical composition and use
US6946146B2 (en) 2001-04-18 2005-09-20 Nostrum Pharmaceuticals Inc. Coating for a sustained release pharmaceutical composition
FR2825023B1 (en) 2001-05-23 2005-04-15 Flamel Tech Sa oral antidiabetic pharmaceutical form "once daily" comprising a biguanide and at least one other active principle
GB0114532D0 (en) 2001-06-14 2001-08-08 Jagotec Ag Novel compositions
HU0401344A2 (en) 2001-08-06 2004-11-29 Euro-Celtique S.A. Pharmaceutical compositions for preventing abuse of opioids, and their preparation procedure
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
CA2456322A1 (en) 2001-08-06 2003-02-20 Euro-Celtique, S.A. Compositions and methods to prevent abuse of opioids
US7332182B2 (en) 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
US7842307B2 (en) 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
JP2005501065A (en) 2001-08-10 2005-01-13 バイヤースドルフ・アクチエンゲゼルシヤフトBeiersdorf Aktiengesellschaft Cosmetic cleansing preparations in which the combination of laureth sulfate and sodium poly-en follower polycarboxylates glycinate compounds based
US20030083286A1 (en) 2001-08-22 2003-05-01 Ching-Leou Teng Bioadhesive compositions and methods for enhanced intestinal drug absorption
US6669955B2 (en) 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
EP1429728A1 (en) * 2001-08-29 2004-06-23 SRL Technologies, Inc. Sustained release preparations
US20030050620A1 (en) 2001-09-07 2003-03-13 Isa Odidi Combinatorial type controlled release drug delivery device
US20040126428A1 (en) 2001-11-02 2004-07-01 Lyn Hughes Pharmaceutical formulation including a resinate and an aversive agent
US20030059397A1 (en) 2001-09-17 2003-03-27 Lyn Hughes Dosage forms
US20030068276A1 (en) 2001-09-17 2003-04-10 Lyn Hughes Dosage forms
FR2830447B1 (en) 2001-10-09 2004-04-16 Flamel Tech Sa oral dosage form microparticle for the delayed and controlled release of active pharmaceutical ingredients
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
GB0124459D0 (en) 2001-10-11 2001-12-05 Novartis Ag Organic compounds
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
CA2464561A1 (en) 2001-10-25 2003-05-01 Depomed, Inc. Methods of treatment using a gastric retained losartan dosage
US20030104052A1 (en) 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US7101572B2 (en) * 2001-12-07 2006-09-05 Unilab Pharmatech, Ltd. Taste masked aqueous liquid pharmaceutical composition
FR2837100B1 (en) 2002-03-18 2004-07-23 Flamel Tech Sa Tablets has bases modified release microcapsules
PL373029A1 (en) 2002-03-18 2005-08-08 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a bile acid sequestering agent
US20050089572A1 (en) 2002-03-22 2005-04-28 Manoj Kumar Controlled release drug delivery system of pravastatin
ES2327034T3 (en) 2002-03-26 2009-10-23 Euro-Celtique S.A. Gel compositions coated with sustained release.
CA2480826C (en) 2002-04-09 2012-02-07 Flamel Technologies Oral pharmaceutical formulation in the form of microcapsule aqueous suspension allowing modified release of active ingredient(s)
WO2003084517A2 (en) 2002-04-09 2003-10-16 Flamel Technologies Oral suspension of amoxicillin capsules
US20050106249A1 (en) 2002-04-29 2005-05-19 Stephen Hwang Once-a-day, oral, controlled-release, oxycodone dosage forms
WO2003094899A1 (en) 2002-05-09 2003-11-20 Diffucap-Chemobras Química E Farmacéutica, Ltda. Novel method of preparing programmed-release compositions containing (s)-1-[n-[1-(ethoxycarbonyl)-3-phenylpropyl]-l-alanyl]-l-proline and the product thus obtained
AU2003229005A1 (en) 2002-05-10 2003-11-11 Merck And Co., Inc. Combination therapy for treating cyclooxygenase-2 mediated diseases in patients at risk of thrombotic cardiovascular events
PL372797A1 (en) 2002-05-31 2005-08-08 Alza Corporation Dosage forms and compositions for osmotic delivery of variable dosages of oxycodone
FR2840614B1 (en) 2002-06-07 2004-08-27 Flamel Tech Sa Polyamino functionalized with alpha-tocopherol and therapeutic applications including
US7399488B2 (en) 2002-07-05 2008-07-15 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opiods and other drugs
NZ520149A (en) 2002-07-12 2003-01-31 Reinforced Concrete Pipes Pty Anchoring device
US20040208936A1 (en) 2002-07-22 2004-10-21 Roland Chorin Novel compositions
FR2842735B1 (en) 2002-07-26 2006-01-06 Flamel Tech Sa Microcapsules modified release of poorly soluble active ingredients for the oral administration
FR2842736B1 (en) 2002-07-26 2005-07-22 Flamel Tech Sa oral pharmaceutical formulation in the form of a plurality of microcapsules for the sustained release principle (s) active (s) slightly soluble (s)
FR2843117B1 (en) 2002-07-30 2004-10-15 Flamel Tech Sa Polyamino acids functionalized by at least one hydrophobic moiety and their therapeutic applications including
US6727839B2 (en) 2002-08-23 2004-04-27 Broadcom Corporation High speed, low power comparator
US7538094B2 (en) 2002-09-19 2009-05-26 Three Rivers Pharmacueticals, Llc Composition containing ribavirin and use thereof
WO2004026262A2 (en) 2002-09-23 2004-04-01 Verion, Inc. Abuse-resistant pharmaceutical compositions
SE0203065D0 (en) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
DE10250084A1 (en) 2002-10-25 2004-05-06 Grünenthal GmbH Abuse-proofed dosage form
TWI332507B (en) 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
US20040110781A1 (en) 2002-12-05 2004-06-10 Harmon Troy M. Pharmaceutical compositions containing indistinguishable drug components
KR20050088311A (en) 2002-12-11 2005-09-05 화이자 프로덕츠 인크. Controlled-release of an active substance into a high fat environment
JP2004188307A (en) 2002-12-11 2004-07-08 Japan Atom Energy Res Inst Method of synthesizing zirconium-deposited fibrous adsorbing material having phosphate group and method of removing arsenic by using the same
ES2350689T3 (en) 2002-12-13 2011-01-26 Durect Corporation Oral delivery system comprising drugs liquid vehicle materials high viscosity.
WO2004056337A2 (en) 2002-12-18 2004-07-08 Pain Therapeutics Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
US20060210620A1 (en) 2003-01-21 2006-09-21 Kumra Pannanchukunnath M Co-precipitated amorphous losartan and dosage forms comprising the same
CA2520321A1 (en) 2003-04-04 2004-10-14 Pharmacia Corporation Oral extended release compressed tablets of multiparticulates
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
SI2279729T1 (en) 2003-07-17 2016-10-28 Banner Life Sciences, LLC Controlled release preparations
DE10336400A1 (en) 2003-08-06 2005-03-24 Grünenthal GmbH Abuse-proofed dosage form
SI1842533T1 (en) 2003-08-06 2013-06-28 Grunenthal Gmbh Dosage form that is secured against misuse
JP2007501806A (en) 2003-08-13 2007-02-01 ハワード ジェイ. スミス アンド アソシエイツ ピーティーワイ エルティーディーHoward J. Smith & Associates Pty Ltd A method of treating a viral infection
US7470435B2 (en) 2003-11-17 2008-12-30 Andrx Pharmaceuticals, Llc Extended release venlafaxine formulation
FR2862536B1 (en) 2003-11-21 2007-11-23 Flamel Tech Sa pharmaceutical formulations for the prolonged release of principle (s) active (s) and their particular therapeutic applications
TWI350762B (en) 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
DK1765292T3 (en) 2004-06-12 2018-01-02 Collegium Pharmaceutical Inc Addiction-prevention drug formulations
DE102004032103A1 (en) 2004-07-01 2006-01-19 Grünenthal GmbH Abuse-proofed, oral dosage form
AU2005259478B2 (en) 2004-07-01 2010-07-15 Gruenenthal Gmbh Oral dosage form safeguarded against abuse containing (1R, 2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
WO2006035417A2 (en) 2004-09-27 2006-04-06 Sigmoid Biotechnologies Limited Dihydropyrimidine microcapsule - formulations
ES2531735T3 (en) 2004-10-15 2015-03-18 Supernus Pharmaceuticals, Inc. pharmaceutical preparations with lower abuse potential
FR2878161B1 (en) 2004-11-23 2008-10-31 Flamel Technologies Sa An oral pharmaceutical composition, solid and designed to prevent misuse
FR2878158B1 (en) 2004-11-24 2009-01-16 Flamel Technologies Sa oral pharmaceutical form, solid microparticulate designed to prevent misuse
FR2881652B1 (en) 2005-02-08 2007-05-25 Flamel Technologies Sa microparticulate oral pharmaceutical form anti-mesuage
FR2889810A1 (en) 2005-05-24 2007-02-23 Flamel Technologies Sa Oral medicinal form, microparticular, anti-measurement
US20070166378A1 (en) * 2005-06-09 2007-07-19 Flamel Technologies, Inc. Oral ribavirin pharmaceutical compositions
WO2006133733A1 (en) 2005-06-13 2006-12-21 Flamel Technologies Oral dosage form comprising an antimisuse system
FR2892937B1 (en) 2005-11-10 2013-04-05 Flamel Tech Sa microparticulate oral pharmaceutical form anti-misuse
US8652529B2 (en) 2005-11-10 2014-02-18 Flamel Technologies Anti-misuse microparticulate oral pharmaceutical form
FR2897267A1 (en) 2006-02-16 2007-08-17 Flamel Technologies Sa Formulations for oral administration multimicroparticulate
US9023400B2 (en) 2006-05-24 2015-05-05 Flamel Technologies Prolonged-release multimicroparticulate oral pharmaceutical form

Also Published As

Publication number Publication date
AU2003246792A1 (en) 2003-10-20
EP1492511B1 (en) 2009-01-07
US20150374636A1 (en) 2015-12-31
CA2480826C (en) 2012-02-07
US20060165807A1 (en) 2006-07-27
US9814684B2 (en) 2017-11-14
DE60325709D1 (en) 2009-02-26
JP2005527573A (en) 2005-09-15
US20110117205A1 (en) 2011-05-19
PT1492511E (en) 2009-04-09
MXPA04009968A (en) 2004-12-13
CN100553625C (en) 2009-10-28
US20170281558A1 (en) 2017-10-05
BRPI0309142B1 (en) 2015-09-22
WO2003084518A2 (en) 2003-10-16
IL164222D0 (en) 2005-12-18
KR20050005438A (en) 2005-01-13
EP1492511B3 (en) 2012-05-02
CN1652755A (en) 2005-08-10
KR101061351B1 (en) 2011-08-31
ES2320438T7 (en) 2013-02-14
CA2480826A1 (en) 2003-10-16
US7906145B2 (en) 2011-03-15
BR0309142A (en) 2005-02-01
ES2320438T3 (en) 2009-05-22
EP1492511A2 (en) 2005-01-05
HK1079448A1 (en) 2010-06-11
US20150374635A1 (en) 2015-12-31
IL164222A (en) 2011-07-31
JP4732696B2 (en) 2011-07-27
WO2003084518A3 (en) 2004-04-01
AU2003246792B2 (en) 2008-08-28
US10004693B2 (en) 2018-06-26
BRPI0309142B8 (en) 2016-09-13

Similar Documents

Publication Publication Date Title
DE60138658D1 (en) Carbamic acid derivatives containing an amide group for the treatment of malaria
DE60230649D1 (en) Systems, methods and devices for the manufacture of tablets
DE60334775D1 (en) Multi-stage oral drug controlled release system
NO20033608L (en) 3- (4-amidopyrrol-2-ylmetliden) -2-indolinonderivater as protein kinase inhibitors
DE60233587D1 (en) Solution applicator
NO20023672D0 (en) Compositions for controlled release
DE60322148D1 (en) Presence and notification system to maintain information and inform
DE60033541D1 (en) Tool for stabilizing bone structures
NO318472B1 (en) palivizumab
DE60235956D1 (en) Aqueous microsphere suspension for downhole cementing
DE60226448D1 (en) Balloon anchor system
DE60217121D1 (en) Drug-containing adhesive
DE60237480D1 (en) Drug-containing adhesive
AT463247T (en) Bupropion metabolites for treatment of anxiety states
DE60314000D1 (en) System for treatment of motion-malfunctions
NO20025827L (en) New microcapsules
NO20030022L (en) Acid addition salts of hydropyridinderivater
NO20032790D0 (en) Hydrophilic polymerkonsentrater
AT384534T (en) Solution for brand-usage
NO20033238D0 (en) Dynamic allocation of bandwidth for multiaksess- communication using avsesjonsköer
AT513530T (en) Dental implant system
RU2004121218A (en) Compounds for the controlled release of active molecules
NO329319B1 (en) Quinoline compounds, processes for their preparation, pharmaceutical preparation and uses of the compounds
DE60332094D1 (en) active pulsspektrophotometrie
DK1198226T3 (en) Oral pharmaceutical controlled release mesalazinsammensætninger

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1492511

Country of ref document: EP